Patents by Inventor Margarita SALCEDO-MAGGUILLI

Margarita SALCEDO-MAGGUILLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230273208
    Abstract: The use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from a disease caused by a coronavirus such as COVID-19 at risk of having or developing a severe form and/or a complication or at risk of death, in a method for assessing the severity of a disease caused by a coronavirus such as COVID-19, and in a method for monitoring a subject suffering from a disease caused by a coronavirus such as COVID-19.
    Type: Application
    Filed: June 7, 2021
    Publication date: August 31, 2023
    Applicants: INOTREM, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE NANCY, UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
    Inventors: Jean-Jacques GARAUD, Marc DERIVE, Margarita SALCEDO-MAGGUILLI, Lucie JOLLY, Sébastien GIBOT, David MOULIN, Mihai NETEA, Aline DE NOOIJER
  • Publication number: 20230201301
    Abstract: An inhibitor of triggering receptor expressed on myeloid cells 1 (TREM-1) for use in the treatment of coronavirus disease 2019 (COVID-19) in a subject in need thereof, in particular in a subject suffering from a severe form and/or a complication of COVID-19. Also, the use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from COVID-19 susceptible to respond to a TREM-1 inhibitor and in a method for monitoring the effectiveness of TREM-1 inhibitor administered to a subject suffering from COVID-19.
    Type: Application
    Filed: June 7, 2021
    Publication date: June 29, 2023
    Applicant: INOTREM
    Inventors: Marc DERIVE, Margarita SALCEDO-MAGGUILLI, Jean-Jacques GARAUD, Simon LAMBDEN, Aurélie OLIVIER
  • Publication number: 20210364532
    Abstract: A method for identifying human subjects suffering from an inflammatory disorder susceptible to respond to a therapy, in particular to a TREM-1 inhibitor. In particular, an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably an acute inflammatory disorder such as SIRS, sepsis or septic shock, susceptible to respond to a therapy, in particular to a TREM-1 inhibitor. The method includes the steps of a) measuring the level of soluble triggering receptors expressed on myeloid cells-1 (sTREM-1) in a biological sample from the human subject, comparing the level of sTREM-1 measured at step a) to a predetermined sTREM-1 value, and c) identifying a human subject suffering from an inflammatory disorder with a level of sTREM-1 measured at step a) higher than the predetermined sTREM-1 value of step b) as susceptible to respond to a therapy, in particular to a TREM-1 inhibitor.
    Type: Application
    Filed: September 27, 2019
    Publication date: November 25, 2021
    Applicant: INOTREM
    Inventors: Marc DERIVE, Aurelie OLIVIER, Kevin CARRASCO, Martin KOCH, Margarita SALCEDO-MAGGUILLI, Amir BOUFENZER, Lucie JOLLY, Jean-Jacques GARAUD